A CRISPR method for genome engineering
Royce Wilkinson and Blake Wiedenheft*

Address: Department of Immunology and Infectious Diseases, Montana State University, Bozeman, MT 59717, USA
* Corresponding author: Blake Wiedenheft (bwiedenheft@gmail.com)

F1000Prime Reports 2014, 6:3 (doi:10.12703/P6-3)
This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial License (http://creativecommons.org/licenses/by-nc/3.0/legalcode), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. You may not use this work for commercial purposes.
The electronic version of this article is the complete one and can be found at: http://f1000.com/prime/reports/b/6/3

Abstract
Clustered regularly interspaced short palindromic repeat (CRISPR) RNA-guided adaptive immune systems that protect bacteria and archaea from infection by viruses are now being routinely repurposed for genome engineering in a wide variety of cell types and multicellular organisms.

Introduction and content
Clustered regularly interspaced short palindromic repeats (CRISPRs) and their associated genes (cas) are essential components of nucleic acid-based adaptive immune systems that are widespread in bacteria and archaea [1-5]. Similar to RNA interference (RNAi) pathways in eukaryotes, CRISPR-mediated immune systems rely on small RNAs for the sequence-specific delivery of dedicated nucleases to invading nucleic acids, such as viruses [2,5]. However, CRISPR systems are phylogenetically and mechanistically distinct from RNAi. Here we provide a brief overview of CRISPR-mediated immunity and explain how the emerging new properties of this defense system are being repurposed for genome engineering in bacteria [6-9], yeast [10,11], human cells [10,12-28], insects [29-32], fish [33-37], worms [38-46], plants [47-54], frogs [55], pigs [56], and rodents [14, 57-61]. The advent of these new genome engineering techniques illustrates how basic research can lead to unexpected innovations with applications in environmental and medical sciences.

Discovering CRISPRs
Each CRISPR locus consists of a series of short repeats that are separated by non-repetitive spacer sequences derived from foreign genetic elements (Figure 1). This conserved repeat-spacer-repeat architecture was originally observed in the Escherichia coli genome in 1987 [62], but the function of these repeats remained enigmatic until 2005, when three groups reported that the spacer sequences in CRISPR loci are often identical to sequences in bacteriophage (phage) genomes and plasmids [63-65]. These observations suggested that CRISPRs might be part of a novel nucleic acid-based immune system designed to protect bacteria and archaea from infection by viruses and other genetic parasites. To test this hypothesis, Barrangou et al. challenged cultures of Streptococcus thermophilus with different phages and then screened for phage-resistant mutants [66]. DNA sequencing of the CRISPR loci from phage-resistant strains of S. thermophilus revealed that the CRISPR locus contained new “spacers” that were derived from the invading phage DNA, and the number of new phage-derived spacers correlated with the degree of phage resistance [66]. In addition, Barrangou and colleagues demonstrated that phage resistance could be genetically enhanced or reduced through insertion or deletion (respectively) of phage-targeting spacer sequences, suggesting that CRISPR-based vaccination programs might be used to protect industrial strains of bacteria from common phage infections.

Stages of CRISPR-mediated defense
Phylogenetic studies have identified distinct versions of the CRISPR system, but adaptive immunity in all of these systems proceeds in three distinct stages: acquisition of foreign DNA, CRISPR RNA (crRNA) biogenesis, and target interference [3,4,67] (Figure 1A). During new sequence acquisition, short fragments of foreign DNA are non-randomly selected and preferentially integrated at one end of the CRISPR locus [68-73]. The addition
Figure 1. Repurposing RNA-guided nucleases from the CRISPR-mediated adaptive immune system in bacteria

A) CRISPR-mediated adaptive immunity proceeds in three distinct stages: acquisition of foreign DNA, CRISPR RNA (crRNA) biogenesis, and target interference. Bacteria acquire resistance to viral and plasmid challengers by integrating short fragments of foreign nucleic acid (called protospacers) into CRISPR loci encoded in the bacterial genome. Protospacers are selected from regions of the genome that are flanked by a short sequence motif called a protospacer adjacent motif (PAM). CRISPR loci consist of a series of short repeats (R, black diamonds) and unique spacers (red and blue lines). CRISPR loci are transcribed and the RNA is processed into a library of small CRISPR-derived RNAs (crRNAs). In some CRISPR systems (i.e. Type II), a trans-activating CRISPR RNA (tracrRNA) is essential for RNA processing and for recognition by Cas9 (CRISPR-associated protein 9). Cas9 is an RNA-guided, dsDNA binding protein that uses two nuclease domains to cleave both strands of target DNA.

B) Cas9 targeting relies on PAM recognition and base pairing between the crRNA and the target DNA. The Cas9 nuclease can be easily programmed to target any DNA sequence with an adjacent PAM by designing a crRNA complementary to the target sequence. Genomic double-stranded DNA breaks are repaired by non-homologous end joining (NHEJ) or homology directed repair (HDR). NHEJ is error-prone, resulting in insertions or deletions (indels) that disrupt the target site. HDR relies on a donor template that can be used to deliver foreign DNA at a specific location. Alternatively, nuclease defective versions of Cas9 (Cas9\(^\text{D}\)) have been tethered to transcription activators (TA) that promote gene transcription, or transcriptional repressors (TR) that inhibit transcription.
of each new “spacer” sequence is accompanied by the duplication of the terminal repeat, thus maintaining the repeat-spacer-repeat architecture of the CRISPR locus [72]. CRISPR loci are transcribed into a long primary transcript that is processed into a library of small crRNAs, each containing a “guide” sequence complementary to a previously encountered invader [74-79]. Each crRNA is bound by one or more CRISPR-associated (Cas) protein(s) and the resulting ribonucleoprotein complex patrols the intracellular environment for targets that are complementary to the crRNA-guide sequence [80-88]. Identified target sequences are cleaved by dedicated nucleases [2,4,5,89]. Some CRISPR systems use crRNAs to target and cleave complementary RNAs, in a process that conceptually resembles eukaryotic RNAi [80,81,90]. However, most CRISPR systems use crRNAs to target invading DNA [91-95]. Many of these DNA targeting systems rely on sophisticated multi-subunit complexes, but one of these systems relies on a single protein called Cas9. Cas9 can be programmed with an RNA to target virtually any complementary DNA sequence [91,96]. The simplicity of the Cas9 system has recently been adopted by a rapidly expanding community of scientists for programmable genetic engineering in microorganisms, cell lines, plants, and animals (Table 1).

Table 1. Applications for RNA-guided Cas9 proteins

| Origin       | Gene       | Purpose | Application | Addgene # | Reference |
|--------------|------------|---------|-------------|-----------|-----------|
| S. pyogenes  | Cas9       | DSB     | in vitro    | 39312     | [96]      |
|              | Cas9<sub>CSN</sub> | SSN    | in vitro    | 39316     |           |
|              | Cas9<sub>SN</sub> | SSN    | in vitro    | 39315     |           |
|              | Cas9<sub>SSN</sub> | dead   | in vitro    | 39318     |           |
| L. innocua   | Cas9       | DSB     | in vitro    | 39313     |           |
| S. thermophilus | Cas9       | DSB     | in vitro    | 39314     |           |
| N. meningitidis | Cas9       | DSB     | in vitro    | 39317     |           |
| S. pyogenes  | hCas9      | editing | hum/mus     | 42234     | [22]      |
|              | hCas9<sub>CSN</sub> | editing | hum/mus     | 42230     | [16]      |
|              | hCas9<sub>SSN</sub> | editing | hum/mus     | 42333     |           |
|              | hCas9<sub>SN</sub> | editing | hum/mus     | 42229     |           |
|              | hCas9<sub>SSN</sub> | editing | hum/mus     | 42333     |           |
| S. pyogenes  | hCas9<sub>SN</sub> | editing | hum/mus     | 41815     | [25]      |
| S. pyogenes  | hCas9      | editing | Bacteria    | 44249     | [8]       |
|              | hCas9<sub>SN</sub> | CRISPRi | Bacteria    | 44246     |           |
|              | hCas9<sub>SN</sub> | CRISPRi | hum/mus     | 44247     |           |
| S. pyogenes  | Cas9       | editing | Bacteria    | 42876     | [7]       |
| S. pyogenes  | Cas9       | editing | Zebrafish   | 42251     | [35]      |
| S. pyogenes  | hCas9      | editing | hum/mus     | 42252     |           |
| S. pyogenes  | hCas9<sub>SSN</sub> | editing | hum/mus     | 43945     | [15]      |
| S. pyogenes  | hCas9<sub>SN</sub> | editing | hum/mus     | 44719     | [18]      |
| S. pyogenes  | hCas9<sub>SN</sub> | editing | hum/mus     | 44720     |           |
| S. pyogenes  | hCas9      | editing | Yeast       | 43802     | [11]      |
| S. pyogenes  | hCas9<sub>SSN</sub> | editing | Yeast       | 43804     |           |
| S. pyogenes  | hCas9<sub>SN</sub> | tracking | hum/mus     | 44738     | [59]      |
| S. pyogenes  | hCas9<sub>SN</sub> | repression | hum/mus    | 46910     | [10]      |
| S. pyogenes  | hCas9<sub>SN</sub> | activation | hum/mus    | 46912     |           |
| S. pyogenes  | hCas9<sub>SN</sub> | repression | Yeast      | 46920     |           |
| S. pyogenes  | hCas9<sub>SN</sub> | repression | Yeast      | 46921     |           |
| S. pyogenes  | hCas9      | editing | Drosophila  | 45945     | [30]      |
| S. pyogenes  | wCas9      | editing | C. elegans  | 46168     | [41]      |
| S. pyogenes  | hCas9      | editing | hum/mus     | 43861     | Unpublished data (Joung Lab) |
| S. pyogenes  | hCas9<sub>SN</sub> | editing | Plants      | 46965     | [49]      |
| S. pyogenes  | zCas9      | editing | Zebrafish   | 47577     | [36]      |
| N. meningitidis | Cas9       | editing | Zebrafish   | 47929     |           |
| S. pyogenes  | wCas9      | editing | C. elegans  | 47549     | [46]      |
| S. pyogenes  | wCas9      | editing | C. elegans  | 47911     | [39]      |
| S. pyogenes  | wCas9      | editing | C. elegans  | 47933     | [42]      |

Cas9<sub>CSN</sub>, (H840A mutant) complementary strand nickase; Cas9<sub>DO</sub>, catalytically inactive/dead; Cas9<sub>SN</sub>, (D10A mutant) non-complementary strand nickase; CRISPRi, CRISPR-interference; DSB, double-strand DNA break; hCas9, mammalian codon optimized; hum/mus, human and mouse; SSN, single-strand nick; wCas9, worm codon optimized; zCas9, zebrafish codon optimized.
A CRISPR boom in biotechnology
Basic research on bacteriophages led to the discovery of DNA restriction endonucleases in the 1970s [97,98]. These enzymes transformed molecular biology by making it possible to cleave specific DNA sequences. Like restriction enzymes, CRISPR systems evolved as components of prokaryotic immune systems that efficiently target nucleic acids for sequence-specific cleavage. However, unlike DNA restriction enzymes, which typically bind to specific 4-8 bp regions of double-stranded DNA (dsDNA), CRISPR RNA-guided systems are extremely versatile and can be easily programmed to target virtually any RNA or DNA substrate. These new RNA-guided nucleases are now being exploited by genome engineers for programmed manipulation of nucleic acids in diverse model systems.

In 2007, Barrangou et al. demonstrated that the CRISPR-mediated immune system in S. thermophilus relied on the cas9 gene for CRISPR-mediated protection from invading viruses [66]. To investigate the mechanism of protection and the fate of phage DNA during the infection, Garneau et al. sequenced viral DNA isolated from infected cells and showed that both stands of the target DNA were cleaved, resulting in a blunt-ended cleavage product [91]. However, at this time the mechanism of generating small CRISPR derived RNA's in this system was not understood. In 2011, Emmanuelle Charpentier’s laboratory reported the identification of a trans-activating crRNA (tracrRNA) with sequences complementary to the repeat sequences of the CRISPR RNA [99]. They show that processing of the long primary CRISPR transcript was dependent on the tracrRNA and an endogenous RNAase III enzyme. Subsequently, Jinek et al. purified the Cas9 protein from Streptococcus pyogenes and showed that Cas9-mediated cleavage of dsDNA relied on both the crRNA-guide and the tracrRNA (Figure 1A) [96]. To simplify these two RNA systems, Jinek et al. made a single chimeric RNA by fusing the 3’ end of the crRNA to the 5’ end of the tracrRNA, and demonstrated that this RNA could target Cas9 to cleave virtually any DNA sequence by design. Similarly, Gasiunas et al. reported purification of the Cas9 protein from Streptococcus thermophilus and demonstrated programmable cleavage of dsDNA targets [100]. Together, mechanistic insights in these papers offered the exciting new possibility of using RNA-guided nucleases to generate dsDNA breaks for targeted genome “editing.”

The principles of genome editing rely on cellular DNA repair systems. The dsDNA breaks introduced by designer nucleases are repaired by either non-homologous end-joining (NHEJ) [101] or homology-directed repair (HDR) [102] (Figure 1B). NHEJ is an error-prone process that is often accompanied by insertion or deletion of nucleotides (indels) at the targeted site, resulting in a genetic knockout of the targeted region of the genome due to frameshift mutations or the insertion of a premature stop codon. Alternatively, HDR relies on template DNA containing sequences homologous to the targeted site to repair the double stranded break. Prior to the discovery of CRISPR RNA-guided nucleases, the most advanced methods for genome editing involved sophisticated protein engineering of zinc finger nucleases (ZFNs), transcription activator-like effector nucleases (TALENs), or homing meganucleases [103,104]. However, protein engineering is expensive and the engineered enzymes sometimes cleave non-target sequences, resulting in off-target effects that are difficult to identify and sometimes toxic. In contrast to the previously existing technologies, CRISPR RNA-guided nucleases rely on simple Watson-Crick base pairing rules that abrogate the need for sophisticated protein engineering. The efficiency and accuracy of RNA-guided genome editing is currently the subject of intense investigation [7,14,17,20,21,24,26,61].

In 2013, less than six months after the reports by Jinek et al. and Mali et al. on the programmable cleavage of dsDNA by Cas9, two Science papers by Cong et al. and Mali et al. demonstrated how RNA-guided Cas9 nucleases could be used to edit genes in mouse or human cell lines [16,25]. To repurpose the Cas9 nuclease for targeted genome editing, the authors fused nuclear localization signals (NLSs) to a codon-optimized version of the cas9 gene and co-expressed this gene with plasmids expressing the tracrRNA and a crRNA-guide, or a single chimeric guide RNA (gRNA) [16,25]. Editing efficiencies by Cas9 were comparable to what has been achieved using ZFNs and TALENs, but using RNAs to program Cas9 for sequence-specific dsDNA breaks is simple, reliable, and cheap. In fact, Ding et al. recently compared the editing efficiency between TALENs and Cas9 at eight different loci in pluripotent stem cells and found that the Cas9-based system “consistently and substantially outperformed” TALENs across all loci [18]. In addition to relying on NHEJ to introduce genetic lesions at programmed cleavage sites, several papers have also now demonstrated that simultaneous delivery of either single-stranded or dsDNA donors can be used to promote HDR [9,11,13,14,18,24,25,28,30,34,38,42,44,46,47,50,56]. A DNA donor identical to the wildtype sequence can be used to restore the original sequence, but DNA donors can also be used to introduce single nucleotide mutations or new genes (Figure 1B). Programmed delivery of foreign DNA to specific locations in the genome suggests that CRISPR RNA-guided nucleases could be used for gene therapy to repair or replace defective genes.
These initial studies have been followed by a rapid succession of papers demonstrating the versatility of RNA-guided Cas9 nucleases for genome engineering. In the last eight months, there have been over 60 independent publications demonstrating how different versions of the guide RNA can be used to target Cas9 to specific sequences for genome engineering in cells as well as multicellular organisms. Cas9-based systems have been used to efficiently generate allelic modifications in early stage embryos [14,29,30,33-37,55,57-61]. This method has been used to make biallelic transgenic knockouts in animals using a single-step process that is profoundly accelerating in vivo genetic studies in live animal systems [14,33-37,55,57-61]. Furthermore, delivery of multiple guide RNAs can be used to edit several genes in a single genome simultaneously or excise large genomic segments located between two different cleavage sites [30,37,44,61]. This approach, called “multiplexing”, has been used to knock out up to five genes in a single embryo [36,57,58,60]. Multiplexing may be particularly useful for knocking out redundant genes or parallel pathways.

The early founders of Cas9-based genome engineering established precedence for resource sharing by making their expression plasmids available to the scientific community at Addgene.org (Table 1). The accessibility of these plasmids, combined with the simplicity of programming Cas9, has contributed to the rapid implementation of this system for target genome engineering. However, the versatility of this platform permits the development of novel applications that go beyond site-specific targeting. Cas9 protein and many of these proteins have different capabilities of Cas9-based systems provide a simple and efficient method for controlling global gene expression that will help untangle complex gene networks and facilitate the development of synthetic organisms with controllable gene expression patterns.

Defining the rules of engagement

Understanding the molecular basis of RNA-guided DNA recognition by Cas9 is critical for implementing this system in a clinical setting. To understand the “rules of engagement”, it is prudent to consider the context in which Cas9 evolved. In the first stage of adaptive immunity, foreign DNA (viral or plasmid) is inserted into the CRISPR locus of the host (Figure 1). Since the CRISPR locus is the template for generating crRNAs, each crRNA is complementary to at least two distinct targets: an invading phage or plasmid sequence (called a protospacer), and the “spacer” sequence in the CRISPR locus of the host. Cas9 avoids “self” (i.e. spacers in the CRISPR) and efficiently targets “non-self” (i.e. protospacers) through protein-mediated recognition of a short sequence motif called a protospacer adjacent motif (PAM). The PAM is an antigenic signature that may promote duplex destabilizations so that the crRNA can access the single-stranded regions of the adjacent DNA sequence for complementary base pairing [96,100].

To quantify how each of these recognition sequences contribute to target cleavage efficiencies by Cas9 from S. pyogenes, Jiang et al. generated a library of targets containing all possible nucleotide substitutions at each position in the protospacer and the PAM [7]. Their results clearly indicate that the NGG motif in the PAM region is the most potent antigen for Cas9 targeting, but a NAG or NNGGN PAM can also elicit Cas9 targeting. In addition to the PAM, they identified a 12-nucleotide “seed sequence” immediately upstream of the PAM that is critical for target recognition. However, the rules of engagement are complex and different mutations display significantly different targeting defects [17]. Furthermore, there are many different variations of the Cas9 protein and many of these proteins have different PAM recognition sequences [13]. Generally speaking, the 12 bases proximal to the PAM are crucial for target recognition, but there are position- and nucleotide-specific effects that alter targeting efficiencies. To determine how these rules apply in the context of human cells, several studies have recently evaluated Cas9-mediated off-target cleavage effects in cultured human cell lines [14,18,20,21,24,26]. These studies reveal that the length of the gRNA can alter efficiency of Cas9 targeting and higher concentrations of the gRNA and Cas9 result in higher frequencies of off-target cleavage effects. These observations are critical to consider during experimental design, and Hsu et al. have developed web-based software to help experimentalists select target sequences that will minimize potential off-target effects [21].

More than Cas9

In the midst of the Cas9 frenzy, other important applications for the CRISPR machinery have been developed. In 2008, Brouns et al. identified a protein in Escherichia coli that exclusively binds and selectively cleaves long CRISPR transcripts into small crRNAs [74]. This protein, called Cas6e (formerly CasE or Cse3) is a member of a large family of extremely diverse proteins that bind and cleave different RNA sequences. These
proteins represent a new class of RNA restriction enzymes with the potential to advance RNA biology in the same way that DNA restriction enzymes did 40 years ago. Recently, activatable CRISPR-associated RNA restriction endoribonucleases have been used for targeted gene regulation in *E. coli* [105] and for affinity purification of RNAs and ribonucleoprotein complexes [106-108].

**A CRISPR future**

The simplicity of programming RNA-guided Cas9 nucleases has contributed to their rapid implementation by the genome engineering community. However, the extent of off-target cleavage and the influence of chromatin structure and modification states on Cas9 cleavage efficiencies remain poorly understood. Early screens for off-target modifications focused on a subset of loci with sequences similar to the authentic target. These initial efforts failed to reveal off-target modifications, but more recent studies performed using high-throughput techniques indicated that high concentrations of Cas9-based nucleases promote off-target cleavage [7,18,24,26,61]. Nevertheless, using higher concentrations of Cas9 also leads to more efficient gene disruption. This suggests a delicate balance between efficiency and accuracy of these nucleases, and methods that enhance their specificity may have significant utility.

We anticipate that the pace of Cas9-based gene modifications will continue to accelerate and that this system will be implemented in increasingly diverse model systems. The simplicity of this system will permit a rapid generation of genome-scale knockout libraries for complex model systems, including human cells, with the potential for *ex vivo* gene therapy in humans. Furthermore, nuclease defective mutants of Cas9 will be tethered to an increasingly diverse array of accessory domains with functions that can be regulated with light (e.g. optogenetics) or chemical treatments. Collectively, Cas9-based technologies are revolutionizing contemporary molecular genetics.

We are still in the infancy of a rapidly evolving field that has focused almost exclusively on the utility of Cas9 proteins from a few organisms (Table 1). While the versatility of Cas9 proteins appears to be limitless, we anticipate that the biochemical, biophysical and target recognition properties of CRISPR RNA-guided complexes from other systems (i.e. Cascade, Cmr, and Csm) will have functional attributes that are desirable in certain contexts. Moreover, we anticipate that anti-CRISPR proteins encoded by some viruses will interact with the components of these systems in unanticipated ways that may lead to new applications for regulating or altering the function of these systems [67,109]. Basic research on the mechanisms of these systems will continue to be the fuel that drives innovation.

**Abbreviations**

Cas, CRISPR-associated; Cas9, CRISPR-associated protein 9; Cas9<sup>Δ9</sup>, nuclease defective mutant of Cas9; CRISPR, clustered regularly interspaced short palindromic repeat; crRNA, CRISPR RNA; dsDNA, double-stranded DNA; gRNA, guide RNA; HDR, homology directed repair; indel, insertion or deletion; NHEJ, non-homologous end-joining; NLS, nuclear localization signal; PAM, protospacer adjacent motif; TA, transcription activator; TALEN, transcription activator-like effector nuclease; TR, transcriptional receptor; tracrRNA, trans-activating crRNA; ZFN, zinc finger nuclease.

**Disclosures**

Blake Wiedenheft is a (co-)inventor on patents related to the application of CRISPRs and their associated genes.

**Acknowledgements**

We are grateful to the CRISPR research community for their exceptional willingness to share expression vectors and other resources. This culture of sharing is largely responsible for the rapid advances in our understanding of Cas9 function and application. We are grateful to members of the Wiedenheft laboratory, Samuel Sternberg, Dipali Sashital and Rachel Haurwitz for the critical reading and thoughtful feedback on this manuscript. The Wiedenheft laboratory is supported by the National Institutes of Health (GM 103500), the National Science Foundation (NSF-EPSCoR, EPS-1101342), the M.J. Murdock Charitable Trust and the Montana State University Agricultural Experimental Station.

**References**

1. Finnern PC, Charpentier E: Memory of viral infections by CRISPR-Cas adaptive immune systems: acquisition of new information. Virology 2012, 434:202-9.
2. Marraffini LA, Sontheimer EJ: CRISPR interference: RNA-directed adaptive immunity in bacteria and archaea. Nat Rev Genet 2010, 11:181-90.
3. Makarova KS, Haft DH, Barrangou R, Brouns SJJ, Charpentier E, Horvath P, Moineau S, Mojica FJM, Wolf YI, Yakunin AF, van der Oost J, Koonin EV: Evolution and classification of the CRISPR-Cas systems. Nat Rev Microbiol 2011, 9:467-77.
4. Sorek R, Lawrence CM, Wiedenheft B: CRISPR-mediated adaptive immune systems in bacteria and archaea. Annu Rev Biochem 2013, 82:237-66.
5. Wiedenheft B, Sternberg SH, Doudna JA: RNA-guided genetic silencing systems in bacteria and archaea. Nature 2012, 482:331-8.
6. Bikard D, Jiang W, Smai P, Hochschild A, Zhang F, Marraffini LA: Programmable repression and activation of bacterial gene
expression using an engineered CRISPR-Cas system. Nucleic Acids Res 2013, 41:7429-37.

7. Jiang W, Bikard D, Cox D, Zhang F, Marraffini LA: RNA-guided editing of bacterial genomes using CRISPR-Cas systems. Nat Biotechnol 2013, 31:233-9.

8. Qi LS, Larson MH, Gilbert LA, Doudna JA, Weissman JS, Arkin AP, Lim WA: Repurposing CRISPR as an RNA-guided platform for sequence-specific control of gene expression. Cell 2013, 152:1173-83.

9. Esvelt KM, Mali P, Braff JL, Moosburner M, Yang SJ, Church GM: Orthogonal Cas9 proteins for RNA-guided gene regulation and editing. Nat Methods 2013, 10:1116-21.

10. Gilbert LA, Larson MH, Morsut L, Liu Z, Brar GA, Torres SE, Stern-Ginossar N, Brandman O, Whitehead EH, Doudna JA, Lim WA, Weissman JS, Qi LS: CRISPR-mediated modular RNA-guided regulation of transcription in eukaryotes. Cell 2013, 154:442-51.

11. DiCarlo JE, Norville JE, Mali P, Rios X, Aach J, Church GM: Genome engineering in Saccharomyces cerevisiae using CRISPR-Cas systems. Nucleic Acids Res 2013, 41:4336-43.

12. Cheng AW, Wang H, Yang H, Shi L, Katz Y, Theunissen TW, Rangarajan S, Shivallia CS, Dadon DB, Jaenisch R: Multiplexed activation of endogenous genes by CRISPR-on, an RNA-guided transcriptional activator system. Cell Res 2013, 23:1163-71.

13. Hou Z, Zhang Y, Propson NE, Howden SE, Chu L, Sontheimer EJ, Thomson JA: Efficient genome engineering in human pluripotent stem cells using Cas9 from Neisseria meningitidis. Proc Natl Acad Sci USA 2013, 110:15644-9.

14. Ran FA, Hsu PD, Lin C, Gootenberg JS, Konermann S, Trevino AE, Scott DA, Inoue A, Matoba S, Zhang Y, Zhang F: Double nicking by RNA-guided CRISPR Cas9 for enhanced genome editing specificity. Cell 2013, 154:1380-9.

15. Cho SW, Kim S, Kim JM, Kim J: Targeted genome engineering in human cells with the Cas9 RNA-guided endonuclease. Nat Biotechnol 2013, 31:230-2.

16. Le Cong, Ran FA, Cox D, Lin S, Barretto R, Habib N, Hsu PD, Wu X, Jiang W, Marraffini LA, Zhang F: Multiplex genome engineering using CRISPR/Cas systems. Science 2013, 339:819-23.

17. Cradick TJ, Fine EJ, Antico CJ, Bao G: CRISPR/Cas9 systems targeting β-globin and CCR5 genes have substantial off-target activity. Nucleic Acids Res 2013, 41:9584-92.

18. Ding Q, Regan SN, Xia Y, Oosterom LA, Cowan CA, Musunuru K: Enhanced efficiency of human pluripotent stem cell genome editing through replacing TALENs with CRISPRs. Cell Stem Cell 2013, 12:393-4.

19. Ebina H, Misawa N, Kanemura Y, Koyanagi Y: Harnessing the CRISPR/Cas9 system to disrupt latent HIV-1 virus. Sci Rep 2013, 3:2510.

20. Fu Y, Foden JA, Khayter C, Maeder ML, Reyon D, Joung JK, Sander JD: High-frequency off-target mutagenesis induced by CRISPR-Cas nucleases in human cells. Nat Biotechnol 2013, 31:822-6.

21. Hsu PD, Scott DA, Weinstein JA, Ran FA, Konermann S, Agarwala V, Li Y, Fine EJ, Wu X, Shalem O, Cradick TJ, Marraffini LA, Bao G, Zhang F: DNA targeting specificity of RNA-guided Cas9 nucleases. Nat Biotechnol 2013, 31:827-32.

22. Jin et al. 2013, 3:2500471.

23. Maeder ML, Linder SJ, Cascio VM, Fu Y, Ho QH, Joung JK: CRISPR RNA-guided activation of endogenous human genes. Nat Methods 2013, 10:977-9.

24. Mali P, Aach J, Stranges PB, Esvelt KM, Moosburner M, Kosuri S, Yang L, Church GM: CAR9 transcriptional activators for target specificity screening and paired nickases for cooperative genome engineering. Nat Biotechnol 2013, 31:833-8.

25. Mali P, Yang L, Esvelt KM, Aach J, Guell M, DiCarlo JE, Norville JE, Church GM: RNA-guided human genome engineering via Cas9. Science 2013, 339:823-6.

26. Pattanayak V, Lin S, Guilinger JP, Ma E, Doudna JA, Liu DR: High-throughput profiling of off-target DNA cleavage reveals RNA-programmed Cas9 nuclease specificity. Nat Biotechnol 2013, 31:839-43.

27. Perez-Pinera P, Kocak DD, Vockley CM, Adler AF, Kabadi AM, Polstein LR, Thakore PI, Glass KA, Ousterout DG, Leong KW, Guilik F, Crawford GE, Reddy TE, Gersbach CA: RNA-guided gene activation by CRISPR-Cas9-based transcription factors. Nat Methods 2013, 10:973-6.

28. Yang L, Guell M, Byrne S, Yang JL, Los Angeles A de, Mali P, Aach J, Kim-Kiselak C, Briggs AW, Rios X, Huang P, Daley G, Church G: Optimization of scarless human stem cell genome editing. Nucleic Acids Res 2013, 41:9049-61.

29. Bassett AR, Tibbet C, Ponting CP, Liu J: Highly efficient targeted mutagenesis of Drosophila with the CRISPR/Cas9 system. Cell Rep 2013, 4:220-8.

30. Gratz SJ, Cummings AM, Nguyen JN, Hamm DC, Donohue LK, Harrison MM, Wildonger J, O'Connor-Giles KM: Genome engineering of Drosophila with the CRISPR RNA-guided Cas9 nuclease. Genetics 2013, 194:1029-35.

31. Yu Z, Ren M, Wang Z, Zhang B, Rong YS, Jiao R, Gao G: Highly efficient genome modifications mediated by CRISPR/Cas9 in Drosophila. Genetics 2013, 195:289-91.

32. Kondo S, Ueda R: Highly improved gene targeting by germ-line-specific cas9 expression in Drosophila. Genetics 2013, 195:715-21.

33. Chang N, Sun C, Gao L, Zhu D, Xu X, Zhu X, Xiong J, Xi J: Genome editing with RNA-guided Cas9 nuclease in zebrafish embryos. Cell Res 2013, 23:465-72.

34. Hwang WY, Fu Y, Reyon D, Maeder ML, Kaini P, Sander JD, Joung JK, Peterson RT, Yeh JJ: Heritable and precise zebrafish genome editing using a CRISPR-Cas system. Proc Natl Acad Sci USA 2013, 110:227-9.

35. Hwang WY, Fu Y, Reyon D, Maeder ML, Tsai SQ, Sander JD, Peterson RT, Yeh JJ, Joung JK: Efficient genome engineering in zebrafish using a CRISPR-Cas system. Nat Biotechnol 2013, 31:227-9.
36. Jao L, Wente SR, Chen W: Efficient multiplex biallelic zebrafish genome editing using a CRISPR nuclease system. Proc Natl Acad Sci USA 2013, 110:13904-9.

37. Xiao A, Wang Z, Hu Y, Wu Y, Luo Z, Yang Z, Zu Y, Li W, Huang P, Tang X, Zhu Z, Lin S, Zhang B: Chromosomal deletions and inversions mediated by TALENs and CRISPR/Cas in zebrafish. Nucleic Acids Res 2013, 41:e141.

38. Chen C, Fenk LA, Bono M de: Efficient genome editing in Caenorhabditis elegans by CRISPR-targeted homologous recombination. Nucleic Acids Res 2013, 41:e193.

39. Ng L, Carroll D, Kim J, Lee J: Heritable Gene Knockout in Caenorhabditis elegans by Direct Injection of Cas9-sgRNA Ribonucleoproteins. Genetics 2013, 195:1177-80.

40. Friedland AE, Tzur YB, Esvelt KM, Colaiácovo MP, Church GM, Calarco JA: Heritable genome editing in C. elegans via a CRISPR-Cas9 system. Nat Methods 2013, 10:741-3.

41. Katic I, Großhans H: Targeted Heritable Mutation and Gene Conversion by Cas9-CRISPR in Caenorhabditis elegans. Genetics 2013, 195:1173-6.

42. Lo T, Pickle CS, Lin S, Ralston EJ, Gurling M, Scharlter CM, Bian Q, Doudna JA, Meyer BJ: Precise and heritable genome editing in evolutionarily diverse nematodes by TALENs and CRISPR/Cas9 to engineer insertions and deletions. Genetics 2013, 195:331-48.

43. Wegrzyn J, Portegejs V, Kerver J, Lemmens BBLG, Tijsterman M, van der Heuvel S, Boxem M: CRISPR/Cas9-Targeted Mutagenesis in Caenorhabditis elegans. Genetics 2013, 195:1187-91.

44. Dickinson DJ, Ward JD, Reiner DJ, Goldberg B: Engineering the Caenorhabditis elegans genome using Cas9-triggered homologous recombination. Nat Methods 2013, 10:1028-34.

45. Peng Z, Zhang B, Ding W, Liu X, Yang D, Wei P, Cao F, Zhu S, Zhang F, Mao Y, Zhu J: Efficient genome editing in plants using a CRISPR-Cas9 system. Cell Res 2013, 23:1229-32.

46. Lu X, Zhao Y, Liu M: Heritable genome editing in C. elegans via a CRISPR-Cas9 system. Nat Biotechnol 2013, 31:684-6.

47. Nishikawa H, Shinagawa H, Makino K, Amemura M, Nakata A: Nucleotide sequence of the iap gene, responsible for alkaline phosphatase isozyme conversion in Escherichia coli, and identification of the gene product. J Bacteriol 1987, 169:429-33.

48. Bolotin A, Quinquis B, Sorokin A, Ehrlich SD: Clustered regularly interspaced short palindromic repeats (CRISPRs) have spacers of extrachromosomal origin. Microbiology (Reading, Engl) 2005, 151:2351-61.

49. Mojica FJM, Diez-Villaseñor C, Garcia-Martínez J, Soria E: Intervening sequences of regularly spaced prokaryotic repeats derive from foreign genetic elements. J Mol Evol 2005, 60:174-82.

50. Pourcel C, Salviogil G, Vergnaud G: CRISPR elements in Yersinia pestis acquire new repeats by preferential uptake of bacteriophage DNA, and provide additional tools for evolutionary studies. Microbiology (Reading, Engl) 2005, 151:653-63.

51. Barrangou R, Fremaux C, Deveau P, Richards M, Boyaval P, Moineau S, Romero D, Horvath P: CRISPR provides acquired resistance against viruses in prokaryotes. Science 2007, 315:1709-12.

52. Wiedenheft B: In defense of phage: viral suppressors of CRISPR-mediated adaptive immunity in bacteria. RNA Biol 2013, 10:886-90.

53. Deveau P, Barrangou R, Garneau JE, Labonte J, Fremaux C, Boyaval P, Romero D, Horvath P, Moineau S: Phage response to CRISPR-encoded resistance in Streptococcus thermophilus. J Bacteriol 2008, 190:1390-400.

54. Horvath P, Romero D, Coûté-Monvoisin A, Richards M, Deveau H, Moineau S, Boyaval P, Fremaux C, Barrangou R: Diversity, activity,
and evolution of CRISPR loci in Streptococcus thermophilus. J Bacteriol 2008, 190:1401-12.

70. Paez-Espino D, Morovic W, Sun CL, Thomas BC, Ueda K, Stahl B, Barrangou R, Banfield JF: Strong bias in the bacterial CRISPR elements that confer immunity to phage. Nat Commun 2013, 4:1430.

71. Swarts DC, Mosterd C, van Passel MWJ, Brouns SJJ: CRISPR interferencedirects strand specific spacer acquisition. PLoS ONE 2012, 7:e35888.

72. Yosef I, Goren MG, Qimron U: Proteins and DNA elements essential for the CRISPR adaptation process in Escherichia coli. Nucleic Acids Res 2012, 40:5569-76.

73. Datseyko KA, Pougach K, Tikhonov A, Wanner BL, Severinov K, Semenova E: Molecular memory of prior infections activates the CRISPR/Cas adaptive bacterial immunity system. Nat Commun 2012, 3:945.

74. Brouns SJJ, Jore MM, Lundgren M, Westra ER, Slijkhuis RJH, Snijders APL, Dickman MJ, Makarova KS, Koonin EV, van der Oost J: Small CRISPR RNAs guide antiviral defense in prokaryotes. Science 2008, 321:960-4.

75. Carte J, Wang R, Li H, Terns RM, Terns MP: Recognition and maturation of effector RNAs in a CRISPR interference pathway. Nat Struct Mol Biol 2011, 18:688-92.

76. Gesner EM, Schellenberg MJ, Garside EL, George MM, Macmillan AM: Sequence and structure-specific RNA processing by a CRISPR endonuclease. Science 2010, 329:1355-8.

77. Haurwitz RE, Jinek M, Wiedenheft B, Zhou K, Doudna JA: Sequence-dependent helicase in the CRISPR/Cas immune system. Nat Struct Mol Biol 2011, 18:670-7.

78. Haurwitz RE, Sternberg SH, Doudna JA: Csy4 relies on an unusual catalytic dyad to position and cleave CRISPR RNA. EMBO J 2012, 31:2824-32.

79. Sashital DG, Jinek M, Doudna JA: An RNA-induced conformational change required for CRISPR RNA cleavage by the endoribonuclease Cse3. Nat Struct Mol Biol 2011, 18:680-7.

80. Hale CR, Majumdar S, Elmore J, Pfister N, Compton M, Olson S, Resch AM, Glover CV, Gravelle BR, Terns RM, Terns MP: Essential features and rational design of CRISPR RNAs that function with the Cas RAMP module complex to cleave RNAs. Mol Cell 2012, 45:292-302.

81. Hale CR, Zhao P, Olson S, Duff MO, Gravelle BR, Wells L, Terns RM, Terns MP: RNA-guided RNA cleavage by a CRISPR RNA-Cas protein complex. Cell 2009, 139:945-56.

82. Jore MM, Lundgren M, van Duijn E, Bultema JB, Westra ER, Waghmare SP, Wiedenheft B, Bul U, Wurm R, Wagner R, Beijer MR, Barendregt A, Zhou K, Snijders APL, Dickman MJ, Doudna JA, Boekema EJ, Heck AJR, van der Oost J, Brouns SJJ: Structural basis for CRISPR RNA-guided DNA recognition by Cascade. Nat Struct Mol Biol 2011, 18:529-36.

83. Lintner NG, Kerou M, Brumfield SK, Graham S, Liu H, Naismith JH, Sdano M, Peng N, She Q, Copié V, Young MJ, White MF, Lawrence CM: Structural and functional characterization of an archael clustered regularly interspaced short palindromic repeat (CRISPR)-associated complex for antiviral defense (CASCADE). J Biol Chem 2011, 286:21643-56.

84. Nam KH, Haitjema C, Liu X, Ding F, Wang H, DeLisa MP, Ke A: Cas5d protein processes pre-crRNA and assembles into a casette-like interference complex in subtype I-C/Dvulg CRISPR-Cas system. Structure 2012, 20:1574-84.

85. Rouillon C, Zhou M, Zhang J, Politis A, Beilstein-Edmonds V, Cannone G, Graham S, Robinson CV, Spagnolo L, White MF: Structure of the CRISPR interference complex CSM reveals key similarities with cascade. Mol Cell 2013, 52:124-34.

86. Spilman M, Coccozaki A, Hale C, Shao Y, Ramia N, Terns R, Terns M, Li H, Stegg S: Structure of an RNA-silencing complex of the CRISPR-Cas Immune system. Mol Cell 2013, 52:146-52.

87. Wiedenheft B, Lander GC, Zhou K, Jore MM, Brouns SJ, van der Oost J, Doudna JA, Nogales E: Structures of the RNA-guided surveillance complex from a bacterial immune system. Nature 2011, 477:486-9.

88. Wiedenheft B, van Duijn E, Bultema JB, Bultema J, Waghmare SP, Waghmare S, Zhou K, Barendregt A, Westphal W, Heck AJR, Heck A, Boekema EJ, Boekema E, Dickman MJ, Dickman M, Doudna JA: RNA-guided complex from a bacterial immune system enhances target recognition through seed sequence interactions. Proc Natl Acad Sci USA 2011, 108:10092-7.

89. Reeks J, Naismith JH, White MF: CRISPR interference: a structural perspective. Biochem J 2013, 453:155-66.

90. Zhang J, Rouillon C, Kerou M, Reeks J, Brugger K, Graham S, Reimann J, Cannone G, Liu H, Albers S, Naismith JH, Spagnolo L, White MF: Structure and mechanism of the CMR complex for CRISPR-mediated antiviral immunity. Mol Cell 2012, 45:303-13.

91. Garneau JE, Dupuis M, Villion M, Romero DA, Barrangou R, Boyaval P, Fremaux C, Horvath P, Magdán AH, Moineau S: The CRISPR/Cas bacterial immune system cleaves bacteriophage and plasmid DNA. Nature 2010, 468:67-71.

92. Mulepati S, Bailey S: In vitro reconstitution of an Escherichia coli RNA-guided immune system reveals unidirectional, ATP-dependent degradation of DNA target. J Biol Chem 2013, 288:22184-92.

93. Sinkunas T, Gasiusas G, Fremaux C, Barrangou R, Horvath P, Siksnys V: Cas3 is a single-stranded DNA nuclease and ATP-dependent helicase in the CRISPR/Cas immune system. EMBO J 2011, 30:1335-42.

94. Sinkunas T, Gasiusas G, Waghmare SP, Dickman MJ, Barrangou R, Horvath P, Siksnys V: In vitro reconstitution of Cascade-mediated CRISPR immunity in Streptococcus thermophilus. EMBO J 2013, 32:385-94.

95. Westra ER, van Erp PBG, Kunne T, Wong SP, Staals RHJ, Seegers CLC, Bollen S, Jore MM, Semenova E, Severinov K, de Vos WM, Dame RT, de Vries R, Brouns SJ, van der Oost J: CRISPR immunity relies on the consecutive binding and degradation of negatively supercoiled invader DNA by Cascade and Cas3. Mol Cell 2012, 46:595-605.

96. Jinek M, Chylinski K, Fontaia I, Hauer M, Doudna JA, Charpentier E: A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity. Science 2012, 337:816-21.

97. Kelly TJ, Smith HO: A restriction enzyme from Hemophilus influenzae. II. J Mol Biol 1970, 51:393-409.
98. Smith HO, Wilcox KW: A restriction enzyme from Hemophilus influenzae. I. Purification and general properties. J Mol Biol 1970, 51:379-91.

99. Deltcheva E, Chylinski K, Sharma CM, Gonzales K, Chao Y, Pirzada ZA, Eckert MR, Vogel J, Charpentier E: CRISPR RNA maturation by trans-encoded small RNA and host factor RNase III. Nature 2011, 471:602-7.

100. Gasiunas G, Barrangou R, Horvath P, Siksnys V: Cas9-crRNA ribonucleoprotein complex mediates specific DNA cleavage for adaptive immunity in bacteria. Proc Natl Acad Sci USA 2012, 109:E2579-86.

101. Lieber MR, Gu J, Lu H, Shimazaki N, Tsai AG: Nonhomologous DNA end joining (NHEJ) and chromosomal translocations in humans. Subcell Biochem 2010, 50:279-96.

102. Heyer W, Ehmsen KT, Liu J: Regulation of homologous recombination in eukaryotes. Annu Rev Genet 2010, 44:113-39.

103. Pauwels K, Podevin N, Breyer D, Carroll D, Herman P: Engineering nucleases for gene targeting: safety and regulatory considerations. N Biotechnol 2013.

104. Perez-Pinera P, Ousterout DG, Gersbach CA: Advances in targeted genome editing. Curr Opin Chem Biol 2012, 16:268-77.

105. Qi L, Haurwitz RE, Shao W, Doudna JA, Arkin AP: RNA processing enables predictable programming of gene expression. Nat Biotechnol 2012, 30:1002-6.

106. Hutin S, Lee Y, Glaunsinger BA: An RNA element in human interleukin 6 confers escape from degradation by the gammaherpesvirus SOX protein. J Virol 2013, 87:4672-82.

107. Lee HY, Haurwitz RE, Apffel A, Zhou K, Smart B, Wenger CD, Laderman S, Bruhn L, Doudna JA: RNA-protein analysis using a conditional CRISPR nuclease. Proc Natl Acad Sci USA 2013, 110:5416-21.

108. Salvail-Lacoste A, Di Tomasso G, Piette BL, Legault P: Affinity purification of T7 RNA transcripts with homogeneous ends using ARiBo and CRISPR tags. RNA 2013, 19:1003-14.

109. Bondy-Denomy J, Pawluk A, Maxwell KL, Davidson AR: Bacteriophage genes that inactivate the CRISPR/Cas bacterial immune system. Nature 2013, 493:429-32.